X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1590) 1590
Book Review (518) 518
Newsletter (424) 424
Publication (137) 137
Newspaper Article (76) 76
Book Chapter (30) 30
Transcript (22) 22
Magazine Article (16) 16
Conference Proceeding (8) 8
Trade Publication Article (4) 4
Web Resource (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
protease inhibitors (1248) 1248
index medicus (1211) 1211
hepatitis c virus (1128) 1128
humans (1103) 1103
proteases (889) 889
hepatitis c (850) 850
antiviral agents - therapeutic use (606) 606
hepatitis c, chronic - drug therapy (525) 525
hepacivirus - genetics (500) 500
hepacivirus - drug effects (499) 499
ribavirin (483) 483
interferon (468) 468
telaprevir (446) 446
antiviral agents (412) 412
boceprevir (407) 407
gastroenterology & hepatology (401) 401
hepatitis (401) 401
health aspects (399) 399
genotype (384) 384
drug therapy, combination (371) 371
biological response modifiers (353) 353
male (348) 348
hepatitis c - drug therapy (338) 338
female (328) 328
proline - analogs & derivatives (318) 318
antiviral agents - pharmacology (317) 317
protease inhibitors - therapeutic use (314) 314
pharmacology & pharmacy (311) 311
protease inhibitor (305) 305
ribavirin - therapeutic use (297) 297
middle aged (293) 293
drug therapy (291) 291
care and treatment (286) 286
viral nonstructural proteins - antagonists & inhibitors (279) 279
research (272) 272
treatment outcome (260) 260
virus diseases (260) 260
hcv (259) 259
genotype 1 infection (251) 251
infection (248) 248
interferon-alpha - therapeutic use (245) 245
virology (242) 242
adult (231) 231
genetic aspects (222) 222
infectious diseases (221) 221
oligopeptides - therapeutic use (220) 220
antiviral agents - adverse effects (215) 215
sustained virological response (213) 213
medical research (210) 210
hepatitis c, chronic - virology (207) 207
proline - therapeutic use (199) 199
analysis (195) 195
virus-infection (195) 195
pharmaceutical industry (192) 192
medicine, experimental (189) 189
polyethylene glycols - therapeutic use (188) 188
gastroenterology and hepatology (187) 187
antiviral agents - administration & dosage (184) 184
therapy (183) 183
treatment-naive patients (182) 182
plus ribavirin (173) 173
protease inhibitors - pharmacology (168) 168
hepacivirus - enzymology (165) 165
drug resistance, viral (164) 164
hepatitis c - virology (163) 163
liver cirrhosis (163) 163
pegylated interferon (158) 158
viruses (158) 158
genotype & phenotype (156) 156
liver (156) 156
aged (153) 153
liver diseases (152) 152
viral nonstructural proteins - genetics (151) 151
sofosbuvir (143) 143
drug resistance (139) 139
recombinant proteins - therapeutic use (138) 138
infections (136) 136
hiv (132) 132
animals (131) 131
hepatology (129) 129
hepatitis-c virus (128) 128
mutation (127) 127
peginterferon (126) 126
drug interactions (124) 124
chemistry, medicinal (123) 123
microbiology (123) 123
peginterferon alpha-2a (123) 123
replication (122) 122
resistance (122) 122
antiviral therapy (120) 120
viral nonstructural proteins - metabolism (120) 120
clinical trials (113) 113
antiviral agents - chemistry (112) 112
genotypes (110) 110
ribavirin - administration & dosage (110) 110
direct-acting antivirals (107) 107
in-vitro (107) 107
viral load (107) 107
chronic hepatitis-c (106) 106
medicine & public health (105) 105
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2088) 2088
Hungarian (18) 18
Spanish (17) 17
French (11) 11
German (10) 10
Korean (5) 5
Russian (5) 5
Croatian (2) 2
Polish (2) 2
Chinese (1) 1
Czech (1) 1
Finnish (1) 1
Hebrew (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 3/2013, Volume 56, Issue 5, pp. 718 - 726
Background. Boceprevir represents a new treatment option for hepatitis C (HCV)—infected patients, including those with HCV/human immunodeficiency virus... 
HIV/AIDS | HIV | Protease inhibitors | Geometric mean | Memory interference | Drug interactions | Infections | Sample mean | Pharmacokinetics | Dosage | Hepacivirus | pharmacokinetics | darunavir | boceprevir | lopinavir | atazanavir | INFECTIOUS DISEASES | PLUS RIBAVIRIN | DRUG-INTERACTIONS | MICROBIOLOGY | IMMUNOLOGY | OATP1B1 | CYP3A | INTERFERON | COCKTAIL | CYTOCHROME-P450 ENZYMES | GENOTYPE 1 INFECTION | Hepacivirus - drug effects | Darunavir | Proline - analogs & derivatives | Area Under Curve | HIV-1 - drug effects | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Oligopeptides - pharmacokinetics | Pyridines - pharmacokinetics | Male | Sulfonamides - pharmacokinetics | Lopinavir - pharmacokinetics | Proline - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Drug Interactions | Ritonavir - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Atazanavir Sulfate | Adult | Female | Boceprevir | Pharmacology, Experimental | Atazanavir | Lopinavir | Dosage and administration | Drug therapy, Combination | Hepatitis C virus | Drug therapy | Health aspects | Clinical trials | Hepatitis | Prescription drugs | Pharmacology | Human immunodeficiency virus--HIV | Index Medicus | All-terrain vehicles | Antiviral agents | Side effects | Ritonavir | Drug interaction | Proteinase inhibitors | Hepatitis C
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 1/2013, Volume 56, Issue 2, pp. 300 - 306
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 01/2014, Volume 39, Issue 1, pp. 93 - 103
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2015, Volume 71, Issue 3, pp. 303 - 311
Journal Article
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 9/2014, Volume 70, Issue 9, pp. 1107 - 1113
Journal Article
Infection, Genetics and Evolution, ISSN 1567-1348, 09/2017, Volume 53, pp. 15 - 23
Journal Article
LANCET INFECTIOUS DISEASES, ISSN 1473-3099, 07/2013, Volume 13, Issue 7, pp. 597 - 605
Background Rates of sustained virological response (SVR) to peginterferon-ribavirin are low in patients with hepatitis C virus (HCV) genotype land HIV. We... 
SUSTAINED VIROLOGICAL RESPONSE | MORTALITY | INFECTIOUS DISEASES | COINFECTED PATIENTS | MANAGEMENT | ALPHA-2A PLUS RIBAVIRIN | C VIRUS | INFECTED PATIENTS | HCV | HUMAN-IMMUNODEFICIENCY-VIRUS | PROTEASE INHIBITOR BOCEPREVIR
Journal Article
Journal Article
Journal Article